Tetra-μ-benzoato-bis­[(3,5-dimethyl­pyridine)­copper(II)]

In the centrosymmetric binuclear title compound, [Cu₂(C₇H₅O₂)₄(C₇H₉N)₂], the Cu^II atom is coordinated by four O atoms from benzoate anions and one N atom from a dimethyl­pyridine ligand. A paddle-wheel-like dimer is formed by two Cu^II ions and four benzoate anions with two 3,5-dimethyl­pyridine ligands at the axial position of the Cu^II ions. The dihedral angle between the two unique benzene rings is 84.26 (16)°. The dihedral angles between the pyridine ring and the benzene rings are 61.67 (15) and 34.27 (14)°. There is π–π stacking of inversion-related pyridine rings, with a centroid–centroid distance of 3.833 (2) Å.

N-(4-Bromo­phen­yl)-2-[(1-cyclo­hexyl­meth­yl-1H-1,2,4-triazol-3-yl)sulfanyl]­acetamide

The title compound, C₁₇H₂₁BrN₄OS, was synthesized as a potential reverse transcriptase (RT) inhibitor of the human immunodeficiency virus type 1 (HIV-1). In the molecule, there is an N—H...S hydrogen bond making a five-membered ring. In the crystal, mol­ecules are connected into centrosymmetric dimers via pairs of N—H...N and weak C—H...N hydrogen bonds. The crystal structure also features C—H...O inter­actions.